Keratoconus progression is not inhibited by reducing eyelid muscular force with botulinum toxin A treatment: a randomized trial
Data
2017
Autores
Renesto, Adimara da Candelaria 
Osaki, Teissy Hentona
Osaki, Midori Hentona
Hirai, Flavio E.
Campos, Mauro
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Purpose: To evaluate whether reducing eyelid muscular force through the administration of botulinum toxin type A (BTX-A) to the orbicularis oculi muscles of patients with keratoconus affected corneal parameters indicative of disease progression. Methods: In this prospective parallel randomized clinical trial, 40 eyes of 40 patients with keratoconus were randomized into equally sized control and BTX-A groups. Patients in the BTX-A group received subcutaneous BTX-A injections into the orbicularis muscle. The control group received no intervention. Palpebral fissure height, best spectacle-corrected visual acuity (BSCVA), and corneal topographic parameters were evaluated at baseline and at 3-, 6-, 12-, and 18-month follow-ups. Results: The mean +/- standard deviation vertical palpebral fissure heights were 9.74 +/- 1.87 mm and 9.45 +/- 1.47 mm at baseline in the control and BTX-A groups, respectively, and 10.0 +/- 1.49 mm and 9.62 +/- 1.73 mm at 18 months, with no significant difference between the groups (p=0.337). BSCVA values were 0.63 +/- 0.56 and 0.60 +/- 0.27 at baseline in the control and BTX-A groups (p=0.643), and 0.52 +/- 0.59 and 0.45 +/- 0.26 at 18 months, again with no significant difference between the groups (p=0.452). In addition, there were no statistical differences between the groups at 18 months for the three keratometry topographic parameters: flattest (K1), steepest (K2), and mean (Km) keratometry (p=0.562). Conclusion: BTX-A inhibition of eyelid force generation did not result in detectable changes in corneal parameters in keratoconic patients during 18 months of follow-up.
Descrição
Citação
Arquivos Brasileiros De Oftalmologia. Sao Paulo, v. 80, n. 2, p. 88-92, 2017.